Filing Flows › Sunshine Biopharma (SBFM) › Q1 2026
Sunshine Biopharma (SBFM) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 13, 2026
Sunshine Biopharma (SBFM) reported revenue of $8.1M for the first quarter 2026 (Q1 2026), -9% from a year earlier and -6% from the quarter before. Operating margin was -17.3%, net loss $1.2M (15.4% of revenue).
Sunshine Biopharma, Q1 2026: revenue $8.1M (-9% year over year), operating margin -17.3%, net loss $1.2M, operating cash flow −$2.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.1M | -6% | -9% |
| Operating profit | −$1.4M | — | — |
| Net earnings | −$1.2M | — | — |
| Operating cash flow | −$2.1M | — | — |
What changed
Revenue was $8.1M in Q1 2026, down 9% year over year and down 6% from the previous quarter.
Gross margin was 27.0%, down 3.7 points from Q1 2025. Operating costs exceeded revenue by $1.4M, an operating margin of -17.3%. Operating expenses fell 11% while revenue fell 9%. The quarter ended with a net loss of $1.2M, narrower than the previous quarter's $2.1M loss.
Operating cash flow was −$2.1M. Non-cash charges added back $77K of depreciation and amortization. Working capital and other items used $905K. Capital expenditures of $5K exceeded it, leaving free cash flow of −$2.1M.
Questions
What was Sunshine Biopharma's revenue in the first quarter 2026?
Sunshine Biopharma (SBFM) reported revenue of $8.1M for the first quarter 2026 (Q1 2026), -9% from a year earlier and -6% from the quarter before.
Was Sunshine Biopharma profitable in the first quarter 2026?
Operating loss was $1.4M (-17.3% of revenue) and net loss $1.2M.
Source: Sunshine Biopharma 10-Q on SEC EDGAR.